Cargando…
Early Hydroxychloroquine Administration for Rapid Severe Acute Respiratory Syndrome Coronavirus 2 Eradication
There are no proven therapeutics for Coronavirus disease 2019 (COVID-19) pneumonia outbreak. We observed and analyzed the clinical efficacy of the most used hydroxychloroquine (HCQ) for 30 days. In this study, administration of HCQ <5 days from diagnosis (odds ratio: 0.111, 95% confidence interva...
Autores principales: | Hong, Kyung Soo, Jang, Jong Geol, Hur, Jian, Lee, Jong Ho, Kim, Hong Nam, Lee, Wonhwa, Ahn, June Hong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Society of Infectious Diseases and Korean Society for Chemotherapy
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7533217/ https://www.ncbi.nlm.nih.gov/pubmed/32757497 http://dx.doi.org/10.3947/ic.2020.52.3.396 |
Ejemplares similares
-
Prognostic Factors for Severe Coronavirus Disease 2019 in Daegu, Korea
por: Jang, Jong Geol, et al.
Publicado: (2020) -
Prognostic Accuracy of the SIRS, qSOFA, and NEWS for Early Detection of Clinical Deterioration in SARS-CoV-2 Infected Patients
por: Jang, Jong Geol, et al.
Publicado: (2020) -
GSK-LSD1, an LSD1 inhibitor, quashes SARS-CoV-2-triggered cytokine release syndrome in-vitro
por: Hong, Kyung Soo, et al.
Publicado: (2020) -
Clinical Features and Outcomes of 98 Patients Hospitalized with SARS-CoV-2 Infection in Daegu, South Korea: A Brief Descriptive Study
por: Hong, Kyung Soo, et al.
Publicado: (2020) -
Radial probe endobronchial ultrasound‐guided transbronchial lung biopsy for the diagnosis of cavitary peripheral pulmonary lesions
por: Hong, Kyung Soo, et al.
Publicado: (2021)